Tariffs May Cost Pharma Billions but Firms Ready to Absorb Hit in 2025

Global pharmaceutical companies could face billions in extra costs if proposed U.S. tariffs on Chinese imports are enacted this year. However, analysts expect most firms to absorb the impact in the short term, thanks to robust margins and global supply diversification.

Under the new plan, the Biden administration is considering a 25% tariff on critical pharmaceutical ingredients from China, aiming to reduce reliance on foreign supply chains. While this move is politically strategic, companies sourcing heavily from China may initially feel the pinch.

Despite the potential cost pressure, most major pharma firms are unlikely to pass on the price hikes to consumers immediately. Industry insiders believe companies will rely on cost buffers, hedging strategies, and diversified sourcing to maintain competitiveness, particularly in the U.S. generics and APIs market.

Indian manufacturers, who supply nearly 40% of the U.S. generics market, are seen as potential winners, as U.S. buyers may seek non-Chinese alternatives. However, the same Indian firms also rely on Chinese raw materials, meaning the tariff’s impact may be indirect but widespread.

Experts suggest that the real effect of tariffs will depend on their duration and enforcement, but in the near term, most pharma companies are expected to weather the storm without major disruption.